S'abonner

The duration of fetal antenatal steroid exposure determines the durability of preterm ovine lung maturation - 28/01/20

Doi : 10.1016/j.ajog.2019.08.046 
Matthew W. Kemp, PhD a, b, c, , Masatoshi Saito, MD, PhD a, b, Augusto F. Schmidt, MD, PhD d, Haruo Usuda, MD a, Shimpei Watanabe, MD b, Shinichi Sato, MD b, Takushi Hanita, MD b, Yusaku Kumagai, MD b, Tsukasa Takahashi, MD b, Gabrielle C. Musk, PhD a, Lucy Furfaro, PhD a, Lisa Stinson, PhD a, Erin L. Fee a, Peter J. Eddershaw, PhD e, Matthew S. Payne, PhD a, Kiara Smallwood a, James Bridges, PhD d, John P. Newnham, MD a, Alan H. Jobe, MD, PhD a, d
a Division of Obstetrics and Gynaecology, The University of Western Australia, Perth, Western Australia, Australia 
b Centre for Perinatal and Neonatal Medicine, Tohoku University Hospital, Sendai, Japan 
c School of Veterinary and Life Sciences, Murdoch University, Perth, Western Australia, Australia 
d Cincinnati Children’s Hospital Medical Centre, Cincinnati, OH 
e GlaxoSmithKline R&D, Stevenage, Hertfordshire, UK 

Corresponding author: Matthew W. Kemp, PhD.

Abstract

Background

Antenatal corticosteroids (ACS) are the standard of care for maturing the fetal lung and improving outcomes for preterm infants. Antenatal corticosteroid dosing remains nonoptimized, and there is little understanding of how different treatment-to-delivery intervals may affect treatment efficacy. The durability of a lung maturational response is important because the majority of women treated with antenatal corticosteroids do not deliver within the widely accepted 1- to 7-day window of treatment efficacy.

Objective

We used a sheep model to test the duration of fetal exposures for efficacy at delivery intervals from 1 to 10 days.

Materials and Methods

For infusion studies, ewes with single fetuses were randomized to receive an intravenous bolus and maintenance infusion of betamethasone phosphate to target 1–4 ng/mL fetal plasma betamethasone for 36 hours, with delivery at 2, 4 ,or 7 days posttreatment or sterile saline solution as control. Animals receiving the clinical treatment were randomised to receive either a single injection of 0.25 mg/kg with a 1:1 mixture of betamethasone phosphate + betamethasone acetate with delivery at either 1 or 7 days posttreatment, or 2 treatments of 0.25 mg/kg betamethasone phosphate + betamethasone acetate spaced at 24 hours (giving ∼48 hours of fetal steroid exposure) with delivery at 2, 5, 7, or 10 days posttreatment. Negative control animals were treated with saline solution. All lambs were delivered at 121 ± 3 days gestational age and ventilated for 30 minutes to assess lung function.

Results

Preterm lambs delivered at 1 or 2 days post–antenatal corticosteroid treatment had significant improvements in lung maturation for both intravenous and single-dose intramuscular treatments. After 2 days, the efficacy of 36-hour betamethasone phosphate infusions was lost. The single dose of 1:1 betamethasone phosphate + betamethasone acetate also was ineffective at 7 days. In contrast, animals treated with 2 doses had significant improvements in lung maturation at 2, 5, and 7 days, with treatment efficacy reduced by 10 days.

Conclusion

In preterm lambs, the durability of antenatal corticosteroids treatment depends on the duration of fetal exposure and is independent of the intravenous or intramuscular maternal route of administration. For acute 24- to 48-hour posttreatment deliveries, a 24-hour fetal antenatal corticosteroids exposure was sufficient for lung maturation. A fetal exposure duration of at least 48 hours was necessary to maintain long-term treatment durability. A single-dose ACS treatment should be sufficient for women delivering within <48 hours of antenatal corticosteroids treatment.

Le texte complet de cet article est disponible en PDF.

Key words : betamethasone, dose, fetus, glucocorticoid, lung maturation, pharmacokinetics, preterm birth, sheep


Plan


 The authors report no conflict of interest
 This work was supported by GlaxoSmithKline Global Health R&D (M.W.K., A.H.J.) and research grant funding from the Bill and Melinda Gates Foundation (OPP1132910 A.H.J., M.W.K.). RapidPoint 500 reagents were generously donated by Siemens Australia; suture materials were kindly donated by Covidien Australia. The above funding organizations had no role in the collection of data or the final decision to publish the study findings, but did contribute to data analysis. M.W.K. is supported by the Women and Infants Research Foundation, Perth, Western Australia and the National Health and Medical Research Council.
 Cite this article as: Kemp MW, Saito M, Schmidt AF, et al. The duration of fetal antenatal steroid exposure determines the durability of preterm ovine lung maturation. Am J Obstet Gynecol 2020;222:183.e1-9.


© 2019  Publié par Elsevier Masson SAS.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 222 - N° 2

P. 183.e1-183.e9 - février 2020 Retour au numéro
Article précédent Article précédent
  • Cumulative effect of evidence-based practices on outcomes of preterm infants born at <29 weeks’ gestational age
  • Angelo Rizzolo, Prakesh S. Shah, Isabelle Boucorian, Brigitte Lemyre, Valerie Bertelle, Ermelinda Pelausa, Marie St Hilaire, Leanne Dahlgren, Marc Beltempo, Canadian Neonatal Network and Canadian Preterm Birth Network Investigators
| Article suivant Article suivant
  • Noninvasive prenatal detection of hemoglobin Bart hydrops fetalis via maternal plasma dispensed with parental haplotyping using the semiconductor sequencing platform
  • Jiexia Yang, Chun-fang Peng, Yiming Qi, Xing-qiang Rao, Fangfang Guo, Yaping Hou, Wei He, Jing Wu, Yang-yi Chen, Xin Zhao, Yu-nan Wang, Haishan Peng, Dongmei Wang, Li Du, Ming-yong Luo, Quan-fei Huang, Hai-liang Liu, Aihua Yin

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.